Stay up-to-date with the latest developments in CDK4/6 inhibition for advanced breast cancer with our expert summary from the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States, 31 May–4 June 2019.
Dr. Joyce A. O’Shaughnessy (Director of Breast Cancer Research at the Baylor-Sammons Cancer Center, Texas and Chair of Breast Cancer Research for The US Oncology Network) reviews the most important emerging data presented at the ASCO Annual Meeting in Chicago, United States, 31 May–4 June 2019 and discusses their potential impact for treating patients with HR+/HER2- advanced breast cancer.
The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.
After watching this touchCONGRESS Webinar, you should be able to:
- Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
- Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
- Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
- What does the treatment landscape look like for HR+/HER2- advanced breast cancer, now and in the future? Focus on the impact of CDK4/6 inhibitors
- What are the latest findings from the ASCO Annual Meeting 2019 for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer? Focus on optimizing treatment sequencing
- What do the data from the ASCO Annual Meeting 2019 tell us about the safety of CDK4/6 inhibitors? Focus on maximizing patient quality of life
Please feedback on this touchCONGRESS Webinar on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).
touchCONGRESS Expert Interviews
Watch a series of internationally renowned clinical specialists from Europe, and the United States discuss key clinical data for advanced breast cancer from the ASCO Annual Meeting 2019 and their potential implications for optimizing patient outcomes, from both global and regional perspectives.Watch Now